Wrap Text
Notification of transactions by persons discharging managerial responsibilities and persons closely associated
Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
(“Mediclinic”, the “Company”, or the “Group”)
26 January 2021
NOTIFICATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
On 25 January 2021, Mr Daniël Meintjes, non-executive director of Mediclinic, sold a total of 18 163
shares in the Company to cover personal tax liabilities. Mr Meintjes continues to hold 123 900 shares
in the Company.
The following notification is made in accordance with Articles 19.1 and 19.3 of the Market Abuse
Regulation.
1. Details of persons discharging managerial responsibilities (“PDMR”)/person closely associated
with them (“PCA”)
a) Name Mr Daniël Petrus Meintjes
2. Reason for the notification
a) Position / status Non-executive director of the Company
b) Initial notification / Initial notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction
monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I 60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial Ordinary Shares
instrument
Identification Code GB00B8HX8Z88
b) Nature of the transaction Sale of shares
c) Price(s) and volume(s) Price(s) per share Volume(s)
ZAR59.50 18 163
d) Aggregated information
Aggregated volume 18 163
Price ZAR59.50 per share
e) Date of the transaction 25 January 2021
f) Place of the transaction JSE
About Mediclinic International plc
Mediclinic is a diversified international private healthcare services group, established in South Africa
in 1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the UAE.
The Group’s core purpose is to enhance the quality of life.
Its vision is to be the partner of choice that people trust for all their healthcare needs.
Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum
of care in such a way that the Group will be regarded as the most respected and trusted provider of
healthcare services by patients, medical practitioners, funders and regulators of healthcare in each of
its markets.
At 30 September 2020, Mediclinic comprised 76 hospitals, eight sub-acute and specialised hospitals,
17 day case clinics and 18 outpatient clinics. Hirslanden operated 17 hospitals and four day case clinics
in Switzerland with more than 1 800 inpatient beds; Mediclinic Southern Africa operations included 52
hospitals (three of which in Namibia), eight sub-acute and specialised hospitals and 11 day case clinics
(four of which operated by Intercare) across South Africa, and more than 8 700 inpatient beds; and
Mediclinic Middle East operated seven hospitals, two day case clinics and 18 outpatient clinics with
more than 900 inpatient beds in the UAE. In addition, under management contracts, Mediclinic Middle
East operates one hospital in Abu Dhabi and will open a 200-bed hospital in the Kingdom of Saudi
Arabia in mid-2022.
The Company’s primary listing is on the London Stock Exchange (“LSE”) in the United Kingdom, with
secondary listings on the JSE in South Africa and the Namibian Stock Exchange in Namibia.
Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private healthcare group
based in the United Kingdom and listed on the LSE.
For further information, please contact:
Company Secretary, Link Company Matters Limited
Jayne Meacham / Caroline Emmet
+44 (0)20 7954 9569
Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181
Media queries
FTI Consulting
Ben Atwell/Ciara Martin – UK
+44 (0)20 3727 1000
Sherryn Schooling – South Africa
+27 (0)21 487 9000
Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Corporate broker: Morgan Stanley & Co International plc and UBS Investment Bank
JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Ltd)
NSX sponsor (Namibia): Simonis Storm Securities (Pty)
Date: 26-01-2021 04:00:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.